use of algorithm in ihc
Post on 31-May-2015
13.051 Views
Preview:
DESCRIPTION
TRANSCRIPT
1
Diagnosis of Diagnosis of TumorsTumors using using
AlgorithmsAlgorithms
Lawrence T. RichardsLawrence T. RichardsM.S.,H.T(ASCP).,QIHC(ASCP).M.S.,H.T(ASCP).,QIHC(ASCP).
2
Diagnosis of Tumors Diagnosis of Tumors using Algorithmsusing Algorithms
A diagnostic algorithm is a method which A diagnostic algorithm is a method which utilizes a panel of antibodies intended to utilizes a panel of antibodies intended to solve a diagnostic problemsolve a diagnostic problem
Many different diagnostic algorithms exist Many different diagnostic algorithms exist and are available in journals and text booksand are available in journals and text books
A diagnostic algorithm is followed by a A diagnostic algorithm is followed by a selective markers for tumor sub selective markers for tumor sub classification.classification.
The panel of antibodies selected should be The panel of antibodies selected should be based on the morphological appearance of based on the morphological appearance of the tissue and the patient’s clinical history the tissue and the patient’s clinical history provided by the physician.provided by the physician.
3
MUC-1 PAS
MUC-1(IHC) PAS (Special Stain)
AdenoCarcinoma (GI)
Special stain vs IHCSpecial stain vs IHC
4
Markers and HistogenesisMarkers and Histogenesis HISTOGENESISHISTOGENESIS MARKERSMARKERS MesenchymalMesenchymal VimentinVimentin EpithelialEpithelial Cytokeratin, EMACytokeratin, EMA Smooth MuscleSmooth Muscle Desmin, HHF35, Desmin, HHF35,
SmActinSmActin Skeletal MuscleSkeletal Muscle MyoglobinMyoglobin FibrohistiocyteFibrohistiocyte CD68, Factor XIIIaCD68, Factor XIIIa Nerve SheathNerve Sheath Leu7,Leu7,Glial fibrillary acidic Glial fibrillary acidic
proteinprotein MelanocyteMelanocyte HMB 45HMB 45 Neuronal Neuronal Neurofilament Neurofilament Endothelial, perivascularEndothelial, perivascular Factor Factor
VIII,CD34,CD31VIII,CD34,CD31 HematopoiticHematopoitic LCA,CD3,CD20,Ki-1LCA,CD3,CD20,Ki-1 NeuroendocrineNeuroendocrine
NSE,Chromogranin,SynaptophysinNSE,Chromogranin,Synaptophysin Ewing’s sarcoma/PNETEwing’s sarcoma/PNET MIC-2(O-13)MIC-2(O-13)
Source:www.moffitt.usf.edu/pubs/ccj/v5nl/department5/htmlSource:www.moffitt.usf.edu/pubs/ccj/v5nl/department5/html
5
Basic Flow ChartBasic Flow ChartSequentialSequential
First Round
(+) ( - )
(+)
(+)
(+)
( - )
( - )
( - )
Second round
6
Use of Panel of Use of Panel of AntibodiesAntibodies
Ab1 Ab1 Ab2Ab2 Ab3Ab3 Ab4Ab4 Ab5 Ab5 Ab6Ab6
+ (-)+ (-) + + (-)(-) + + + Tumor-1+ Tumor-1
(-)(-) ++ (-)(-) ++ (-)(-) (-) Tumor-2(-) Tumor-2
7
Differential ApplicationDifferential Application
Tumor 1Tumor 1 Tumor 2Tumor 2 Ab1 +Ab1 + Ab1 –Ab1 – Ab2 -Ab2 - Ab2 +Ab2 +
8
Diagnostic AlgorithmDiagnostic Algorithmfor unknown Tumor Typefor unknown Tumor Type
CarcinoCarcinomama
LymphoLymphomama
MelanoMelanomama
SarcomaSarcoma NotesNotes
Pan Pan KeratinKeratin
PositivePositive NegativeNegative NegativeNegative NegativeNegative ForFor
Poorly Poorly differentiatedifferentiated malignant d malignant tumor tumor differentiatiodifferentiationn
Caution:Caution:
Variation in Variation in cellular cellular pattern can pattern can misleadmislead
(+)(+) and and (-)(-)..
LCALCA NegativeNegative PositivePositive NegativeNegative NegativeNegative
S 100 / S 100 / HMB45/HMB45/
MART-1MART-1
TyrosinaseTyrosinase
NegativeNegative NegativeNegative PositivePositive NegativeNegative
DesminDesmin NegativeNegative NegativeNegative NegativeNegative PositivePositive
VimentinVimentin NegativeNegative NegativeNegative PositivePositive PositivePositive
Source adopted from: DAKO training manual
9
Undifferentiated Undifferentiated Malignant NeoplasmMalignant Neoplasm
Abs toAbs to Abs/Abs/cloneclone
CarcinoCarcinomama
LymphoLymphomama
MelanoMelanomama
SarcomaSarcoma
CytokerCytokeratinatin
AE1/AE3AE1/AE3
VimentinVimentin V9V9
MelanoMelanoma ma antigenantigen
HMB 45HMB 45
CD 45CD 45 PD7/2B1PD7/2B111
CD43CD43
Almost always positive
Almost always Negative Sometimes positive
Sometimes negative
Gowen AM.Diagnostic Immunohistochemistry of Solid Tumors: Strategies and Solutions,USCAP;2002 #35
10
Carcinoma of Carcinoma of Unknown PrimaryUnknown Primary
The hypothesis is that the The hypothesis is that the primary tumor either remains primary tumor either remains
microscopic and escapes clinical microscopic and escapes clinical detection or disappears after detection or disappears after
seeding the metastasis.seeding the metastasis.
Antibody AlgorithmAntibody Algorithm is used to is used toSearch for primary SiteSearch for primary SiteRule out Non-Carcinoma Rule out Non-Carcinoma
Like lymphoma, melanoma, Like lymphoma, melanoma, sarcomasarcoma
Identify Sub-Groups for Identify Sub-Groups for TreatmentTreatment
11
: >90% of tumors positive*
: 50-90% of tumors positive*
:
10-50% of tumors positive*
: <10% of tumors positive*
? : Insufficient evidence[ ]
: Staining of secondary (non-neoplastic) cell type
( )
:Staining dependant on antibody
* Positive Generally : unequivocal staining of =10% of tumor cells
Threshold for PositivityThreshold for Positivity
+/-
+
-/+
(-)
12
Metastatic Adenocarcinoma ofMetastatic Adenocarcinoma of unknown origin
with site specific markerswith site specific markers
PSA+(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
+
+
+
+
+
+
+
Prostate
Lung
Stomach/PancreasBreast
Colon
Colon
Stomach / Pancreas
Breast
Ovary
Pancreas,(Ovary serous)
Stomach / Pancreas
Breast / Stomach / Pancreas
Source: www.clincancerres.aacrjournals.org/egi/content/full/11/10/3766
TTF-1
GCDFP15
CDX2 / CK20
ER
CA125
Mesothelin
Lysozyme
+
+
+
(-)
(-)
(-)
CDX2
CK 7
Mesothelin
MC5+ (98%)
13
Details of Abs used in the Details of Abs used in the AlgorithmAlgorithmAbsAbs CloneClone SourceSource DilutionDilution A RA R
CA 125CA 125 Ov185:1Ov185:1 NovocastroNovocastro 1:4001:400 HIERHIER
CDX2CDX2 AMT28AMT28 NovocastroNovocastro 1:1001:100 HIERHIER
CK7CK7 OV-TLOV-TL DAKODAKO 1:5001:500 HIERHIER
CK20CK20 Ks20.8Ks20.8 DAKODAKO 1:5001:500 HIERHIER
ERER 6F116F11 NovocastroNovocastro 1:501:50 HIERHIER
GCDFP-15GCDFP-15 23A323A3 NovocastroNovocastro 1:201:20 HIERHIER
LYSOZOMELYSOZOME POLYPOLY NovocastroNovocastro 1:50001:5000 ENZYMATIENZYMATICC
MESOTHELIMESOTHELINN
5B25B2 NovocastroNovocastro 1:201:20 HIERHIER
PSAPSA ER-PR8ER-PR8 DAKODAKO 1:1001:100 HIERHIER
TTF-1TTF-1 SPT249SPT249 NovocastroNovocastro 1:501:50 HIERHIER
Dennis JL et al.Clinical Cancer Research;11:3766-3772,2005
14
Algorithm for Tumors of Algorithm for Tumors of Unknown OriginUnknown Origin
MarkerMarker Tumor ofTumor of % Sensitivity% Sensitivity % Specificity% SpecificityPSAPSA ProstateProstate 100100 9999
TTF-1TTF-1 LungLung 9191 9898
CDX-2CDX-2 ColonColon 8383 9696
CDX-2CDX-2 Colon and Colon and StomachStomach 5656 9898
CK20CK20 ColonColon 6868 9191
CK20CK20Colon,Stomach,Colon,Stomach,
PancreasPancreas 3636 9797
GCDFP-15GCDFP-15 BreastBreast 5454 9696
ERER Breast and OvaryBreast and Ovary 7474 9595
CA 125CA 125 Ovary and Ovary and PancreasPancreas 8888 8888
MesothelinMesothelin Ovary and Ovary and PancreasPancreas 8585 8585
LysozymeLysozyme Stomach and Stomach and PancreasPancreas 6565 6969
CK7CK7 Stomach and Stomach and PancreasPancreas 7272 9696
Gross Cystic Disease Fluid Protein
Source:www.clincancerres.aacrjournals.org/content/vol11/issue10
15
Differential DiagnosisDifferential Diagnosis Bladder vs Bladder vs
Prostate ca Prostate ca
Cytokeratin Cytokeratin 77
++ (-)(-)
Cytokeratin Cytokeratin 2020
++ (-)(-)
CEACEA ++ (-)(-)
PAPPAP (-)(-) ++
PSAPSA (-)(-) ++
Goldstein N.Immunohistochemical Antibody Panels to help Identify the Primary Sites of Various Carcinomas;ASCP Teleconference # 2109
16
Mesothelioma or
Small Cell Carcinoma ?
17
Mesothelioma vs CarcinomaMesothelioma vs CarcinomaAntigenAntigen Mesothelioma %Mesothelioma % Carcinoma %Carcinoma %
CytokeratinCytokeratin 100100 100100
EMAEMA 8080 100100
ThrombomodulinThrombomodulin 100100 88
Leu-M1Leu-M1 1010 7575
S-100S-100 1010 8585
CEACEA 00 1515Placental Alkaline Placental Alkaline PhosphatasePhosphatase
00 6565
VimentinVimentin 4040 3030
Ber-EP4Ber-EP4 00 8080
CalretininCalretinin 9090 3030
B72.3B72.3 00 7070Brown RW et al.Multiple-marker immunohistochemical phenotypes distinguishing malignant Brown RW et al.Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol.1993;24:347-354pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol.1993;24:347-354
18
Cytokeratin Cytokeratin phenotypephenotype CK phenotypeCK phenotype CK7 (-) / CK 20 CK7 (-) / CK 20
(-)(-)
CK7 (+) / CK 20 CK7 (+) / CK 20 (-)(-)
CK7 (-) / CK 20 CK7 (-) / CK 20 (+)(+)
CK7 (+) / CK 20 CK7 (+) / CK 20 (+)(+)
TumorsTumors HNC, Liver, Lung (SqCC and HNC, Liver, Lung (SqCC and
SmCC),Prostate, RenalSmCC),Prostate, Renal
Biliary and Pancreas, Breast, Biliary and Pancreas, Breast, Cervical, EM, Lung(Ad ca), Cervical, EM, Lung(Ad ca), Ovarian (non-mucinous), Ovarian (non-mucinous), thyroidthyroid
Colon, Gastric, Markel C caColon, Gastric, Markel C ca
Biliary and Pancreas, Ovarian Biliary and Pancreas, Ovarian (Mucinous), Urothelial.(Mucinous), Urothelial.
Source: Adopted from Dennis JL, Clin Cancer Res 2005
19
Cytokeratin for Carcinoma Cytokeratin for Carcinoma DiagnosisDiagnosis
CK5CK5 CK7CK7 CK20CK20Breast Ca DuctalBreast Ca Ductal ★★ ● ● ○ ○Lung nonsmall CellLung nonsmall Cell ○ ○ ● ● ○ ○ (non SqCCa) (non SqCCa) Lung SqCCaLung SqCCa ● ● ★ ★ ○ ○Pancreatic Ca Pancreatic Ca ○ ○ ★ ★ ★ ★ Colorectal Ad Ca Colorectal Ad Ca ○ ○ ○ ○ ● ●Mesothelioma Mesothelioma ● ● ● ● ○ ○Prostatic Ad CaProstatic Ad Ca ○ ○ ○ ○ ○ ○ Transitional Cell CaTransitional Cell Ca ● ● ● ● ● ●
★ ★ May be Positive ● Positive ○ NegativeMay be Positive ● Positive ○ Negative
Source: A.M.Gown ASCP Course #35Source: A.M.Gown ASCP Course #35
20
Prostate Ca or Prostate Ca or Benign ?Benign ?
Prostate Prostate CancerCancer EpCam +EpCam + ATM +ATM + AMACR +AMACR + PSA + / (-)PSA + / (-) 3434ßE12 (-) almost allßE12 (-) almost all p63 (-) almost allp63 (-) almost all Prostein +Prostein + NKX3.1 + NKX3.1 +
Benign Benign ProstateProstate
EpCam (-)EpCam (-) ATM (-) / +ATM (-) / + AMACR (-)AMACR (-) PSA + / (-)PSA + / (-) 3434ßE12 +ßE12 + p63 +p63 + Prostein +Prostein + NKX3.1 + NKX3.1 +
Hammerich KH et al.Application of Immunohistochemistry to the Genitourinary System(Prostate, Urinary Bladder, Testis, and Kidney)Archives of Pathology and Laboratory Medicine;132:432-440,2007
ATM=ataxia-telangiectasia mutated;AMACR=alpha-methylacyl-CoA racemase;Ep-Cam=epithelial transmembrane glycoprotein
21
Urothelial Ca vs Urothelial Ca vs Prostate CaProstate Ca
EMAEMA CK7CK7 P63P63 CK5/6CK5/6 EpCamEpCam CD57CD57 PSAPSA PAPPAP NKX3.NKX3.
11 ProsteiProstei
nn
++ --++ --+/-+/- 00+/-+/- 00+/-+/- 00
-/+-/+ +/-+/- 00 ++
00 +/-+/- 00 ++ 00 ++ 00 ++
Urothelial ca Prostate ca
Hammerich KH.Archives of Pathology and Laboratory Medicine;132(3):432-440
Urothelial ca
Prostate ca
22
Ab CocktailsAb Cocktails Breast CaBreast Ca: : ER + GCDFP-15ER + GCDFP-15 MelanomaMelanoma: : MART-1+Melan MART-1+Melan
A+Tyrosine +A+Tyrosine +
PNL2PNL2 Basal Cell MarkerBasal Cell Marker: : p63 + 34betaE12 p63 + 34betaE12
+ +
CK5/6CK5/6 Endocrine Ca:Endocrine Ca: Chrom A+NSE +Chrom A+NSE +
SynaptophysinSynaptophysin Pan SarcomaPan Sarcoma: Vim + Coll IV + CD 99: Vim + Coll IV + CD 99
23
Endocervical Ad.Ca & Endocervical Ad.Ca & Endometrial Mucinous Endometrial Mucinous
Ad.CaAd.CaECAECA
MUC-1(-)MUC-1(-) ER(-)ER(-) PR(-)PR(-) P16(+)P16(+)
EMMAEMMA MUC-1 (+)MUC-1 (+) ER(+)ER(+) PR(+)PR(+) P16(-)P16(-)
Khoury T et al.BMC Clin Path 2006;6:1
24
A, Normal post-menopausal endometrium (H&E, 20x); B, MUC1 immunostain in normal postmenopausal endometrium showing “pure apical” staining pattern (x20); C, normal endocervical glands (H&E, 20x); D, MUC1 immunostain in normal endocervical glands showing A/C staining pattern, (x20).
MUC1-Purely Apical vs Apical & Cytoplasmic
Khoury T, et al.BMC Clin Pathol.2006;6:1
25
Characteristics of Characteristics of antibodies used for antibodies used for
evaluation.evaluation. Antibody/Clone/Source/Antigen retrieval/DilutionAntibody/Clone/Source/Antigen retrieval/Dilution MUC1 Ma695 Novocastra, Hi temp 1:100MUC1 Ma695 Novocastra, Hi temp 1:100
P16 E6H4 DAKO, TRS 1:25 P16 E6H4 DAKO, TRS 1:25 Vim Vim3B4 DAKO, TRS 1:1000Vim Vim3B4 DAKO, TRS 1:1000
ER 1D5 DAKO, TRS/Vector 1:100ER 1D5 DAKO, TRS/Vector 1:100PR PgR636 DAKO, TRS/Vector 1:200PR PgR636 DAKO, TRS/Vector 1:200
Khoury Khoury et al.et al. BMC Clinical PathologyBMC Clinical Pathology 2006 6:1 doi:10.1186/1472- 2006 6:1 doi:10.1186/1472-6890-6-16890-6-1
26
The Cost-Effectiveness of The Cost-Effectiveness of IHCIHC
Why do IHC assay?Why do IHC assay? To increase patient life expectancy by correctTo increase patient life expectancy by correct
diagnosis and treatment plan.diagnosis and treatment plan. To increase diagnostic certaintyTo increase diagnostic certainty To predict patient prognosisTo predict patient prognosis
eg., 35yr old female, history of Br ca, radical eg., 35yr old female, history of Br ca, radical mastectomy performed earlier. Now mastectomy performed earlier. Now diagnosed with cirrhosis and liver mass.diagnosed with cirrhosis and liver mass.
1.1. Meatastatic Ad Ca ?Meatastatic Ad Ca ?2.2. Hepato Cellular Ca ?Hepato Cellular Ca ?
27
LastlyLastly
“ “The Diagnostic Power of any The Diagnostic Power of any Immunohistochemical Procedure Immunohistochemical Procedure is no Greater than the wisdom of is no Greater than the wisdom of the Pathologist interpreting it.” the Pathologist interpreting it.”
Dr.Allen GownDr.Allen Gown
Thank You all.Thank You all.
top related